The content on this site is intended for healthcare professionals only
Prof Sven Mahner talks to ecancer at the 2012 International Gynaecologic Cancer Society meeting in Vancouver about a retrospective study looking at treatment of vulva cancer in the adjuvant setting.
Vulva cancer, a rare disease with an increase of incidence especially in younger patients, has very few trials in progress due to the rarity of the disease.
This study on adjuvant treatment collected data and analysed treatment modalities and prognostic factors retrospectively.
Results looked at 500 node positive patients and that found those treated with adjuvant therapy had 30 percent longer survival than those without.
Filming supported by Amgen
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients
Advancements in paediatric Acute lymphoblastic leukemia management
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC
Choosing the right patients for transplant
Choosing Wisely in endometrial & cervix cancers: Medical therapy
Low-dose olanzapine after highly emetogenic chemotherapy can be the new standard of care for solid tumours
